- Home
- ALXO vs ACRV Comparison
ALXO vs ACRV Comparison
Compare ALXO & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- ACRV
- Stock Information
- Founded
- ALXO 2015
- ACRV 2018
- Country
- ALXO United States
- ACRV United States
- Employees
- ALXO N/A
- ACRV N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- ALXO Health Care
- ACRV Health Care
- Exchange
- ALXO Nasdaq
- ACRV Nasdaq
- Market Cap
- ALXO 56.8M
- ACRV 47.8M
- IPO Year
- ALXO 2020
- ACRV 2022
- Fundamental
- Price
- ALXO $1.05
- ACRV $1.51
- Analyst Decision
- ALXO Strong Buy
- ACRV Buy
- Analyst Count
- ALXO 6
- ACRV 7
- Target Price
- ALXO $3.30
- ACRV $17.40
- AVG Volume (30 Days)
- ALXO 1.7M
- ACRV 3.4M
- Earning Date
- ALXO 11-06-2025
- ACRV 11-12-2025
- Dividend Yield
- ALXO N/A
- ACRV N/A
- EPS Growth
- ALXO N/A
- ACRV N/A
- EPS
- ALXO N/A
- ACRV N/A
- Revenue
- ALXO N/A
- ACRV N/A
- Revenue This Year
- ALXO N/A
- ACRV N/A
- Revenue Next Year
- ALXO N/A
- ACRV $805.34
- P/E Ratio
- ALXO N/A
- ACRV N/A
- Revenue Growth
- ALXO N/A
- ACRV N/A
- 52 Week Low
- ALXO $0.40
- ACRV $1.05
- 52 Week High
- ALXO $2.36
- ACRV $10.00
- Technical
- Relative Strength Index (RSI)
- ALXO 54.14
- ACRV 55.81
- Support Level
- ALXO $1.01
- ACRV $1.46
- Resistance Level
- ALXO $1.27
- ACRV $2.67
- Average True Range (ATR)
- ALXO 0.12
- ACRV 0.19
- MACD
- ALXO -0.02
- ACRV 0.02
- Stochastic Oscillator
- ALXO 29.03
- ACRV 15.33
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.